Gunning, B. (Boudewijn)
- Publications
- item.page.relationships.isContributorAdvisorOfPublication
- item.page.relationships.isContributorOfPublication
Search Results
Now showing 1 - 1 of 1
- Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome A Randomized Clinical Trial(2020) Gil-Nagel, A. (Antonio); Sanchez-Carpintero, R. (Rocío); Knappertz, V. (Volker); Saneto, R.P. (Russell P.); Dunayevich, E. (Eduardo); Checketts, D. (Daniel); Gunning, B. (Boudewijn); Miller, I. (Ian); Perry, M.S. (M. Scott); Scheffer, I.E. (Ingrid E.)Question Is adjunctive cannabidiol at doses of 10 and 20 mg/kg/d superior to placebo in reducing convulsive seizure frequency in patients with Dravet syndrome? Findings This double-blind clinical trial randomized 199 children with Dravet syndrome to cannabidiol (10 or 20 mg/kg/d) or matched placebo for 14 weeks. Convulsive seizure frequency compared with baseline was reduced by 48.7% in the 10-mg/kg/d cannabidiol group and 45.7% in the 20-mg/kg/d cannabidiol group vs 26.9% in the placebo group. Meaning Both doses of adjunctive cannabidiol were similarly efficacious in reducing convulsive seizures associated with Dravet syndrome.